In the real world, things are not as tidy as in clinical trials. For instance, some users of Zetia, Tricor/TriLipix, and Niaspan are not at their LDL goal; although it seems more doubtful based on what we now know, for these users we can’t say for sure that adding an HDL-raising or TG-lowering agent does not help.
I presume from the post I’m replying to that you do not think the AIM-HIGH failure is bullish for AMRN.
US Niaspan scripts are down only 5% as a result of the AIM-HIGH study, according to ABT’s 2Q11 CC, so this product is indeed stickier than some investors and analysts thought.
News 
Market Data 
Discover 
AI
